Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Polaryx Therapeutics, Inc. Common Stock

PLYX

Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.

Last trade $1.62
Day change -$0.05 (-2.99%)
Day range $1.49 – $1.86
Volume 26,687
Market cap $83M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$83.24M
Price / earnings
—
Price / book
10.94×
Price / sales
—
EV / sales
—
EV / EBITDA
-11.22×

Profitability

Earnings per share
-$0.15
Return on assets
-84.23%
Return on equity
-95.28%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
8.62×
Quick ratio
8.62×
Cash ratio
8.45×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$7.42M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PLYX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026
Revenue$0$0$0
Cost of revenue$0$0$0
Gross profit$0$0$0
Selling, general and administrative$877K$661K$1.28M
Research and development$2.45M$719K$679K
Total operating expenses$3.33M$1.38M$1.96M
Operating income-$3.33M-$1.38M-$1.96M
Interest expense$0$0$0
Income before taxes-$3.33M-$1.38M-$2.54M
Income taxes$0$0$0
Net income-$3.33M-$1.38M-$2.54M
Net income attributable to common shareholders-$3.33M-$1.38M-$2.54M
EBITDA-$3.33M-$1.38M-$1.96M
Basic earnings per share-$0.07-$0.03-$0.05
Diluted earnings per share-$0.07-$0.03-$0.05

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial

Polaryx Therapeutics (PLYX) announced it remains on schedule to initiate its Phase 2 SOTERIA basket trial in the fourth quarter of 2026, evaluating lead candidate PLX-200 across four rare pediatric lysosomal storage disorders. The company has secured FDA authorization, engaged a CRO, obtained Fast Track Designation across all four indications, and completed a $10 million financing to support trial initiation and clinical milestones.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.